Yissum - Research Development Company of the Hebrew University posted this:iCOUGH: Accumulative Breath Cougher for Spinal Cord InjuriesThe device incorporates an active drug delivery PEP valve device that provides active, accumulative dosing of large volume of aerosolized drug or air. This technology enables the distribution of the substance to the lower respiratory system. also incorporated is a Venturi-based insufflation-exhalation system that simulates cough by predefined parameters activated independently or by stimuli from the patient Project ID : 40-2018-4614
uacoopera posted this:
Licensing Manager at uacoopera
Jordi Reverter posted this:
Licensing Manager at Institut Català de Nanociència i Nanotecnologia
uacoopera posted this:
Licensing Manager at uacoopera
Yissum - Research Development Company of the Hebrew University posted this:A Novel Target for Treatment of Rare Genetic Diseases Caused by Nonsense MutationsDuchenne Muscular Dystrophy (DMD) and Becker Dystrophy Molecules tested on patient-derived cells: 5-AzaC, Ataluren, Amlexanox, +8 new drugs Project ID : 6-2018-4579
Yissum - Research Development Company of the Hebrew University posted this:Novel Indoline Derivatives as Anti-Inflammatory Agents for the Treatment of DiabetesNovel Indoline Derivatives as Anti-Inflammatory Agents for the Treatment of Diabetes Project ID : 7-2015-3171
Universidad de Alcalá-OTRI posted this:Carbosilane dendrons functionalized with fatty acids: Formation of micelles and uses in biomedicine as antiviral, antibacterial, antiprionic, antimicrobial and drug transporters.The research group of the University of Alcalá in «Dendrimers for biomedical applications» presents the following invention that refers to the formation of dendrons of carbosilane structure that have in their periphery preferably anionic or cationic groups and in the focal point fatty acids or derivatives of these. Its main field of application is in biomedicine, as non-viral transport agents, as drug transporters, to elaborate a drug, as antimicrobial, antiviral or antipyretic agents. In the environmental sector we also find its application as biocides for water treatment. The group seeks to reach license agreements, collaboration or commercial agreements with technical assistance with companies from the sector of Health, Pharma and Environment.
NDI Foundation posted this:Strain of bacteriorhodopsin-BRBacteriorhodopsin (BR) is the newest biotechnological product that will make a revolution in many spheres of life: from medicine to defense. Data on the production of the BR in the world is hidden. From open sources - the only seller (and, possibly, producer) is an American company SIGMA, selling BR for research. We offer developed strain of BR. A method of producing allows to get BR in large quantities to several kg. The strain is certified and stored in special depositories. BR has unique qualities - the main one is - memory. For BR, it was necessary to find a special strain - producer of BR. Just several countries has the strain (USA, Russia, ..), other data hidden. We also developed such an unique strain.
Yissum - Research Development Company of the Hebrew University posted this:CBD treatment for Hepatic Encephalopathy, Liver Cirrhosis, and NASHA method for the treatment of hepatic encephalopathy comprising administering to a subject in need of such treatment an effective amount of D9-tetrahydrocannabinol (THC) or Cannabidiol. Small molecule keywords: hepatic, encephalopathy Originally: 12-2007-1885, 12-2007-1878 12-2006-577- 3 projects combined into one Project ID : 12-2006-577
Yissum - Research Development Company of the Hebrew University posted this:Novel Compounds for Treatment and Prevention of Autismbeta- carotene as treatment for autism, Functional Foods & Ingredients, Other Disease Project ID : 6-2014-3058
Yissum - Research Development Company of the Hebrew University posted this:Topical Treatment of Skin Toxicities Caused by Biological Anti-Cancer DrugsCluster8 Many of the antineoplastic tyrosine kinase inhibitors are associated with prominent and sometimes dose-limiting dermatologic complications. Of severe clinical implication are the specific EGFR inhibitors. Most patients treated with these drugs suffer from severe impairment to their quality of life and require reduction or interruption in the anti-cancer drug protocols. Treatment strategies today for treating skin toxicities from EGFR inhibitors show limited benefit and most patients require dose reductions or interruptions to the anti-cancer treatment protocols. Our proposal focuses on the development of a novel approach using formulation for treating skin toxicities caused by anti-neoplastic EGFR inhibitors by applying topical compounds that specifically and locally block the anti-cancer drugs. Our preliminary results have shown that blocking EGFR inhibitors binding to EGFR prevents keratinocyte death. We have identified small compounds that block EGFR inhibitors binding to its receptor and have developed topical slow release system that can deliver the target compounds to the hair follicle which is a major target for skin rash caused by EGFR inhibitors. Our novel approach will improve the quality of life of patients suffering from skin toxicity and help maintain an optimal anti-neoplastic dose thereby allowing more patients to receive full dose anti-cancer therapy and improve response to therapy Project ID : 6-2017-4450
Yissum - Research Development Company of the Hebrew University posted this:Novel Autotaxin Inhibitor Drug for Cancer and Asthma (XIIPHONATE)Cluster8 We propose a novel compound for the treatment of asthma. We suggest to use this new compound named XIIPHONATE as new lipid-mimetic molecule that inhibits recombinant Autotaxin (ATX), as a potential local, long-term treatment for asthma. This approach is based on the fact that a novel bioactive lipid mediator, Lysophosphatidic acid (LPA), has a pivotal role in the pathogenesis of asthma. It was reported that LPA is synthesized from LPC through the enzymatic activity of ATX. Clinical data show that the levels of ATX protein, and LPA are significantly elevated the in airspaces of patients with asthma. Thus, XIIPHONATE, will inhibit LPA overproduction that leads to the pathologic state. It will therefore present a new therapeutic modality for asthma. Project ID : 6-2016-4268
Universidad de Alcalá-OTRI posted this:Carbosilane dendrimers with a polyphenolic nucleus and their use as antiviralsThe research group in «Dendrimers for biomedical applications» of the University of Alcalá presents carbosilane dendrimers with a polyphenolic nucleus, its obtaining procedure and its uses as antiviral, antibacterial and antifungal agents. The group seeks to reach collaboration agreements, licensing or commercial agreements with technical assistance, with companies from the biotechnology, pharmaceutical and biomedicine sectors in general.
Universidad de Alcalá-OTRI posted this:Carbosilane dendrimers and their use as antiviralsThe research group in "Dendrimers for Biomedical Applications" of the University of Alcalá presents these highly branched macromolecules synthesized from a polyfunctional nucleus, of carbosilane structure and functionalized in its periphery with anionic groups that give the macromolecule a negative net charge. In addition, the invention relates to the use of the dendrimers as an antimicrobial and the process for obtaining them. The group seeks to reach collaboration agreements, licensing or commercial agreements with technical assistance, with companies in the biotechnology, pharmaceutical and biomedicine sectors in general.